Skip to Content

Sunitinib Use After Chemotherapy

Randomized Phase III, Double-Blind Placebo Controlled Trial of Sunitinib as Maintenance Therapy in Non-progressing Patients Following an Initial Four Cycles of Platinum-based Combination Chemotherapy in Advanced Stage IIIB/IV NSCLC

Objective

Patients with advanced stage IIIB/IV non-small cell lung cancer may be eligible for this study. Patients will be randomized to receive either Sunitinib or placebo after standard chemotherapy to see if Sunitinib helps their tumor shrink or stop growing.

IRB Protocol Number
CALGB 30607
Principal Investigator(s)
Charles Catcher, MD

Clinical Trial Categories

  • Lung Cancer
Sponsor(s)
National Cancer Institute
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000